Treatment - Page 25 of 471 Posts on Medivizor

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Posted by Medivizor on Apr 26, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) versus obinutuzumab with chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL) that have never received treatment (treatment-naive). This study concluded that the...

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Posted by Medivizor on Apr 26, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the oncological effectiveness of intraoperative radiotherapy (IORT) and whole breast irradiation (WBI) for patients with early breast cancer (BC). This study concluded that there was a high oncological effectiveness for both groups of patients. Some background Intraoperative...

Evaluating the risk of developing secondary rectal cancer after radiotherapy in patients with prostate cancer.

Posted by Medivizor on Apr 14, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the risk of developing secondary rectal cancer after radiotherapy (RT) in patients with prostate cancer. The data showed that RT significantly increased the risk of developing secondary rectal cancer in these patients. Some background Prostate cancer (PCa) is one of the most common form of cancer found in men. PCa...

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Posted by Medivizor on Apr 14, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that...

Evaluating the safety and effectiveness of optimized conformal total body irradiation in children with with blood cancer who received TCRαβ/CD19-depleted grafts

Posted by Medivizor on Apr 10, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate optimized conformal (OC) total body irradiation (TBI) in pediatric patients with blood cancers who received further chemotherapy and allogeneic hematopoietic stem cell transplant (alloHSCT) with TCRαβ/CD19 depletion. This study concluded that OC-TBI is a...

Evaluating the long-term effectiveness and safety of thulium laser enucleation of the prostate treatment for patients with benign prostatic hyperplasia.

Posted by Medivizor on Apr 10, 2022 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of thulium laser enucleation of the prostate (ThuLEP) treatment for patients with benign prostatic hyperplasia (BPH). The data showed that ThuLEP treatment was safe and effective over the long term in these patients. Some background BPH is the non-cancerous increase in the size...

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Posted by Medivizor on Apr 10, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM). The data showed that the addition of ixazomib to lenalidomide maintenance improved survival without cancer...

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with chronic pelvic pain syndrome and erectile dysfunction.

Posted by Medivizor on Apr 10, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study evaluated the effectiveness and safety of low-intensity extracorporeal shock wave therapy (LSWT) for patients with chronic pelvic pain syndrome (CPPS) and erectile dysfunction (ED). The data showed that LSWT was safe and effective in improving the symptoms of these patients. Some background CPPS is lower abdominal pain usually...

Evaluating the effectiveness and feasibility of patient-reported outcome-based symptom management versus usual care in patients after lung cancer surgery.

Posted by Medivizor on Apr 10, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and feasibility of patient-reported outcome (PRO)-based symptom management versus usual care in patients after lung cancer surgery. The data showed that PRO-based symptom management after lung cancer surgery showed lower symptom burden and fewer complications than usual care for up to 4 weeks after...

Evaluating the effectiveness of anatomical versus non-anatomical resection in the surgery of lung metastases in patients with colorectal cancer.

Posted by Medivizor on Apr 10, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of anatomical resection (AR) versus non-anatomical resection (NAR) in the surgery of lung metastases for patients with colorectal cancer (CRC). The data showed AR significantly improved cancer-specific survival outcomes compared to NAR in the surgery of lung metastases for patients with CRC. Some...

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Posted by Medivizor on Apr 10, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness of adding ribociclib (Kisqali) to endocrine (hormone) therapy in pre-/perimenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding ribociclib to hormone therapy significantly improved survival outcomes than hormone...

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...

Treatment Posts on Medivizor

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Evaluating the risk of developing secondary rectal cancer after radiotherapy in patients with prostate cancer.

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Evaluating the safety and effectiveness of optimized conformal total body irradiation in children with with blood cancer who received TCRαβ/CD19-depleted grafts

Evaluating the long-term effectiveness and safety of thulium laser enucleation of the prostate treatment for patients with benign prostatic hyperplasia.

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with chronic pelvic pain syndrome and erectile dysfunction.

Evaluating the effectiveness and feasibility of patient-reported outcome-based symptom management versus usual care in patients after lung cancer surgery.

Evaluating the effectiveness of anatomical versus non-anatomical resection in the surgery of lung metastases in patients with colorectal cancer.

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Categories

Recent Posts

Archives

Treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email